Bongers Marloes E J, de Lorijn Fleur, Reitsma Johannes B, Groeneweg Michael, Taminiau Jan A J M, Benninga Marc A
Department of Pediatric Gastroenterology and Nutrition, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands.
Nutr J. 2007 Apr 11;6:8. doi: 10.1186/1475-2891-6-8.
Nutrilon Omneo (new formula; NF) contains high concentration of sn-2 palmitic acid, a mixture of prebiotic oligosaccharides and partially hydrolyzed whey protein. It is hypothesized that NF positively affects stool characteristics in constipated infants.
Thirty-eight constipated infants, aged 3-20 weeks, were included and randomized to NF (n = 20) or a standard formula (SF; n = 18) in period 1 and crossed-over after 3 weeks to treatment period 2. Constipation was defined by at least one of the following symptoms: 1) defecation frequency < 3/week; 2) painful defecation; 3) abdominal or rectal palpable mass.
Period 1 was completed by 35 infants. A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36). Improvement of hard stool consistency to soft stool consistency was found more often with NF than SF, but did not reach statistical significance (90% versus 50%; RR, 1.8; 95% CI, 0.9-3.5; p = 0.14). No difference was found in painful defecation or the presence of an abdominal or rectal mass between the two groups. Twenty-four infants completed period 2. Only stool consistency was significantly different between the two formulas (17% had soft stools on NF and hard stools on SF; no infants had soft stools on SF and hard stools on NF, McNemar test p = 0.046).
The addition of a high concentration sn-2 palmitic acid, prebiotic oligosaccharides and partially hydrolyzed whey protein resulted in a strong tendency of softer stools in constipated infants, but not in a difference in defecation frequency. Formula transition to NF may be considered as treatment in constipated infants with hard stools.
诺优能蕴荟（新配方；NF）含有高浓度的sn-2棕榈酸、益生元低聚糖混合物和部分水解乳清蛋白。据推测，NF对便秘婴儿的粪便特征有积极影响。
纳入38名3至20周龄的便秘婴儿，在第1阶段将其随机分为NF组（n = 20）或标准配方奶粉组（SF；n = 18），3周后交叉进入第2治疗阶段。便秘定义为至少出现以下症状之一：1）排便频率<每周3次；2）排便疼痛；3）腹部或直肠可触及肿块。
35名婴儿完成了第1阶段。两组的排便频率均显著增加（NF组：治疗前3.5次/周，治疗后5.6次/周；SF组：治疗前3.6次/周，治疗后4.9次/周），但两种配方奶粉之间无显著差异（p = 0.36）。与SF组相比，NF组更常出现硬便质地改善为软便质地的情况，但未达到统计学意义（90%对50%；RR，1.8；95%CI，0.9 - 3.5；p = 0.14）。两组在排便疼痛或腹部或直肠肿块方面无差异。24名婴儿完成了第2阶段。两种配方奶粉之间仅在粪便质地方面存在显著差异（17%的婴儿食用NF时为软便，食用SF时为硬便；没有婴儿食用SF时为软便，食用NF时为硬便，McNemar检验p = 0.046）。
添加高浓度的sn-2棕榈酸、益生元低聚糖和部分水解乳清蛋白，使便秘婴儿的粪便有明显变软的趋势，但排便频率无差异。对于粪便硬的便秘婴儿，可考虑转用NF配方奶粉进行治疗。
